JYANT Technologies
JYANT Technologies, Inc. is an early stage product development company founded in 2010, focused on developing and delivering disruptive therapies and diagnostics for unmet medical needs in oncology and inflammatory diseases. The company leverages its strong intellectual property and patented technologies, including anti-chemokine and anti-chemokine receptor antibodies, nanotechnology, and novel manufacturing methods, to provide solutions for diagnosis and treatment of cancers and inflammatory conditions. JYANT aims to bring medical products to market faster through its innovative platform and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
Patents
Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US-8796422-B2
View Details
Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US-8796422-B2
View DetailsProducts
Antibody therapeutics targeting chemokines/chemokine receptors
Therapeutic antibody candidates directed at chemokines and chemokine receptors for oncology and inflammatory disease indications; development includes antibodies for CXCL9, CXCL10, CXCL11, CXCL13, CCL25 and receptors such as CXCR3, CXCR5, CCR9.
Fusion polypeptide (chemokine-immunoglobulin / chemokine-polymer) antagonists
Chemokine-immunoglobulin and chemokine-polymer/PEG fusion polypeptides designed to block chemokine receptors with high affinity and extended serum half-lives for treatment of receptor-mediated disorders.
Nanoformulated therapeutic and diagnostic particle platforms
Nano- and micro-particle platforms produced by planetary ball milling and controlled formulation to encapsulate therapeutics, biologics, diagnostics, and insoluble molecules for mucosal or parenteral delivery.
Antibody therapeutics targeting chemokines/chemokine receptors
Therapeutic antibody candidates directed at chemokines and chemokine receptors for oncology and inflammatory disease indications; development includes antibodies for CXCL9, CXCL10, CXCL11, CXCL13, CCL25 and receptors such as CXCR3, CXCR5, CCR9.
Fusion polypeptide (chemokine-immunoglobulin / chemokine-polymer) antagonists
Chemokine-immunoglobulin and chemokine-polymer/PEG fusion polypeptides designed to block chemokine receptors with high affinity and extended serum half-lives for treatment of receptor-mediated disorders.
Nanoformulated therapeutic and diagnostic particle platforms
Nano- and micro-particle platforms produced by planetary ball milling and controlled formulation to encapsulate therapeutics, biologics, diagnostics, and insoluble molecules for mucosal or parenteral delivery.
Services
Collaboration formation with academic and industry partners to support discovery, development, and delivery of therapeutic and diagnostic candidates.
Collaboration formation with academic and industry partners to support discovery, development, and delivery of therapeutic and diagnostic candidates.
Expertise Areas
- Chemokine-targeted therapeutics
- Fusion protein therapeutic development
- Nanoparticle formulation and nano-compounding
- Biomarker-based diagnostics
Key Technologies
- Monoclonal antibody therapeutics
- Chemokine and chemokine receptor targeting
- Immunoglobulin-fusion polypeptides
- PEGylation and polymer conjugation
News & Updates
Received a $300,000 Small Business Technology Transfer (STTR) R41 CA214080-01 grant from the NIH for developing anti-CCL25 monoclonal antibody to treat castration resistant prostate cancer.
Received US patent #9,249,204 for compositions and methods of making CXCR4 protein antagonists for cancer and inflammatory diseases.
Filed an amicus brief in the Sequenom, Inc. v. Ariosa Diagnostics, Inc. case to clarify patent-eligible inventions under the Mayo precedent and 35 U.S.C. § 101.
Received US patent #9,233,120 for preventing and treating cancers using anti-CCL25 and -CCR9 antibodies.
Received a $315,320 NIH STTR grant for targeting the CXCL13-CXCR5 axis in prostate cancer, especially in African Americans.
Received a $300,000 Small Business Technology Transfer (STTR) R41 CA214080-01 grant from the NIH for developing anti-CCL25 monoclonal antibody to treat castration resistant prostate cancer.
Received US patent #9,249,204 for compositions and methods of making CXCR4 protein antagonists for cancer and inflammatory diseases.
Filed an amicus brief in the Sequenom, Inc. v. Ariosa Diagnostics, Inc. case to clarify patent-eligible inventions under the Mayo precedent and 35 U.S.C. § 101.
Received US patent #9,233,120 for preventing and treating cancers using anti-CCL25 and -CCR9 antibodies.
Received a $315,320 NIH STTR grant for targeting the CXCL13-CXCR5 axis in prostate cancer, especially in African Americans.